New insights into mineral and skeletal regulation by active forms of vitamin D. (Q36366492)

13 August 2017

1 reference

title

New insights into mineral and skeletal regulation by active forms of vitamin D. (English)

1 reference

13 August 2017

0 references

G N Hendy

1

1 reference

13 August 2017

K A Hruska

series ordinal

2

1 reference

13 August 2017

S Mathew

series ordinal

3

1 reference

13 August 2017

D Goltzman

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

69

1 reference

13 August 2017

2

1 reference

13 August 2017

218-223

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000091

13 August 2017

0 references

cites work

Vitamin D: more than a "bone-a-fide" hormone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Overview of general physiologic features and functions of vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Response element binding proteins and intracellular vitamin D binding proteins: novel regulators of vitamin D trafficking, action and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Molecular nature of the vitamin D receptor and its role in regulation of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Does calcitriol have actions independent from the vitamin D receptor in maintaining skeletal and mineral homeostasis?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Vitamin D resistant rickets with alopecia: a form of end organ resistance to 1,25 dihydroxy vitamin D

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Aberrant growth plate development in VDR/RXR gamma double null mutant mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Osteoblast differentiation and control by vitamin D and vitamin D metabolites.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Low dose calcitriol versus placebo in patients with predialysis chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Soft tissue calcification in pediatric patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Vascular calcification in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Aortic pulse wave velocity index and mortality in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Active serum vitamin D levels are inversely correlated with coronary calcification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Warfarin-induced artery calcification is accelerated by growth and vitamin D

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000091

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000091

1 reference

13 August 2017

1 reference